
As Enhertu sweeps across the entire HER2 breast cancer treatment landscape, the big question facing the industry is: What comes next? Here's a deep dive #BCAM fiercebiotech.com/biotech/ad…

Biopharma reporter @FiercePharma & @FierceBiotech. Medill MSJ 16

As Enhertu sweeps across the entire HER2 breast cancer treatment landscape, the big question facing the industry is: What comes next? Here's a deep dive #BCAM fiercebiotech.com/biotech/ad…

Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer. #ESMO26 fiercepharma.com/pharma/amge…

In his first interview as FDA's oncology chief, Dr. Angelo de Claro vows to "continue the innovation that the OCE is known for." fiercepharma.com/pharma/firs…

Akeso CEO agrees that $SMMT needs a Big Pharma partner to back ivonescimab. FYI, $MRK just pubbed the first global trial for its PD-1xVEGF on registry: a solid tumor ph.2 with sac-TMT fiercepharma.com/pharma/akes…

Merck briefly posted—and then rapidly deleted—a new trial listing testing its PD-1xVEGF bispecific (MK-2010) combined with its TROP2 ADC (sac-TMT). fiercebiotech.com/biotech/me…

89% PFS, 62% OS improvements from J&J's MonumenTAL-6 trial for bispecific doublet Tecvayli and Talvey in 2L+ multiple myeloma. fiercepharma.com/pharma/jj-b…

After a 4-month investigation, Nature has decided to retract viral PD-1 study that tied lung cancer survival to treatment timing fiercepharma.com/pharma/natu…

Thanks, Jacob. Means a lot coming from a fellow journalist whose work I admire.
V nice story from @Angus_Fierce on trial design differences & changes for PD(L)1xVEGF bispecifics fiercebiotech.com/biotech/ne… $BNTX $PFE $BMY

#ASCO26: For Akeso's HARMONi-6, ivonescimab's 34% overall survival improvement versus PD-1 inhibitor in their chemo combos in first-line squamous NSCLC draws both hope and scrutiny at #ASCO2026 fiercepharma.com/pharma/asco…

Merck's first PD-1xVEGF bispecific data are here: 55% unconfirmed ORR in a small group of first-line NSCLC patients #AACR26 fiercebiotech.com/biotech/me…

In other words, FDA still took the full standard 60-day filing review period for a CNPV, even though this is an sNDA of an existing drug filed under RTOR, which means the review should have started before the entire submission package was completed.

The FDA's press release says zongertinib's application was FILED on Jan. 13, 2026. But Boehringer told us that they actually completed the package under real-time oncology review on Nov. 14, 2025, and that it was ACCEPTED on Jan. 13.
A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing! fda.gov/news-events/press-an…

FDA unveils ‘plausible mechanism pathway,’ a new approach that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved. fiercebiotech.com/biotech/fd…

Was just wondering what Vivek's been up to.
Vivek Ramaswamy set to launch Ohio governor bid on Feb. 24 trib.al/8DJ4C6p


Akeso, Summit's ivonescimab crushes Merck's Keytruda in China study, signaling potential new standard of care in lung cancer #WCLC24 fiercepharma.com/pharma/akes…